Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,823 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05969171RecruitingPhase 2
Surufatinib plus chemotherapy for advanced pancreatic cancer
This Phase 2 study tests whether adding surufatinib to first-line treatment (either AG or a similar AG-based regimen) can improve outcomes for people with locally advanced or metastatic pancreatic cancer. You may be considered if your cancer cannot be removed by surgery and you’ve already had a short course of similar treatment with a response.
ShanghaiAges 18–75 - NCT06662006RecruitingPhase 2
Nal-IRI chemo with immunotherapy and radiation for pancreatic cancer
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
Nanjing, JiangsuAges 18–75 - NCT06576115RecruitingPhase 2
Combination therapy with device for metastatic pancreatic cancer
This trial tests whether adding a non-invasive device that uses low-level radio waves to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with pancreatic cancer that has spread to other parts of the body.
Clarkston, MichiganAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
RAS-targeting drugs for gastrointestinal cancers
This trial tests new drugs that target a specific genetic change (RAS) in gastrointestinal cancers like pancreatic and colorectal cancer. The goal is to see if these drugs can shrink or slow down the cancer.
Chandler, ArizonaAges 18 years+ - NCT06453486RecruitingPhase 2
High dose radiation for pancreatic cancer after chemo
This trial tests whether giving a strong, focused dose of radiation can help people with locally advanced pancreatic cancer that has shrunk or stayed stable with first-line chemotherapy. It aims to improve outcomes for those who cannot have surgery.
Toronto, OntarioAges 18 years+ - NCT06346197RecruitingPhase 3
Immunotherapy combo for advanced MSI-H stomach/esophageal cancer
This trial tests a combination of immune checkpoint inhibitors (nivolumab, botensilimab, and balstilimab) plus chemotherapy for people with advanced stomach or esophageal cancer that has a specific genetic instability (MSI-H/dMMR) and expresses PD-L1. It may be an option for those who haven't had prior immunotherapy or chemotherapy for advanced disease.
BrestAges 18 years+ - NCT03080974RecruitingPhase 2
Study tests immunotherapy plus electroporation for advanced pancreatic cancer
This Phase 2 study looks at whether adding immunotherapy to a procedure called irreversible electroporation can help treat stage III pancreatic cancer. You might be eligible if you have measurable tumors and can safely undergo the procedure.
Louisville, KentuckyAges 18 years+ - NCT06030622RecruitingPhase 1/Phase 2
Treatment for advanced pancreatic cancer after standard therapy
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
Brooklyn, New YorkAges 18 years+ - NCT05919238RecruitingPhase 1
Padeliporfin treatment for non-removable pancreatic cancer
This Phase 1 study tests a new cancer treatment called padeliporfin given through a special catheter to treat pancreatic ductal adenocarcinoma that cannot be removed by surgery. It aims to see how safe the treatment is and whether it can help control the tumor in people who are not surgical candidates.
Duarte, CaliforniaAges 18 years+ - NCT04570943RecruitingPhase 2
Pancreatic cancer treatment: chemo first, then targeted MRI-guided radiation
This Phase 2 trial tests giving specific chemotherapy in sequence, then using MRI-guided focused radiation to treat locally advanced, non-removable pancreatic cancer. It may help shrink or control the tumor while aiming radiation more precisely using MRI.
Marseille, Bouches-du-RhôneAges 18–75 - NCT05630989Recruiting
Registry for outcomes in KRAS G12R pancreatic cancer on MEK therapy
This study keeps a registry (a secure database) to track how people with advanced pancreatic cancer and a KRAS G12R mutation do after treatment with a MEK inhibitor–based combination. It helps doctors understand which outcomes matter most for this specific genetic type of cancer.
Milwaukee, WisconsinAges 18 years+ - NCT05482893RecruitingPhase 1/Phase 2
Study of spevatamig for advanced gastrointestinal cancers
This trial tests a new drug called spevatamig (PT886) alone or with other treatments for advanced stomach, gastric, pancreatic, bile duct, or colorectal cancers. The goal is to see if it helps slow or stop cancer growth.
Duarte, CaliforniaAges 18 years+ - NCT04222413RecruitingPhase 1
Study of metarrestin for advanced solid tumors
This study tests an experimental drug called metarrestin for people with solid tumors that have spread or come back after standard treatment. It may help by targeting a protein involved in cancer cell growth.
Fairway, KansasAges 12–120 - NCT01954992RecruitingPhase 3
Glufosfamide vs 5-FU for metastatic pancreatic cancer after gemcitabine
This study compares two chemotherapy drugs—glufosfamide and 5-FU—in people with pancreatic cancer that has spread and got worse after gemcitabine. It aims to see which option works better as a “second-line” treatment.
Whittier, CaliforniaAges 18 years+ - NCT04205968RecruitingPhase 2
Testing ramucirumab with chemo for advanced small bowel cancer
This trial studies whether adding ramucirumab to chemotherapy (either paclitaxel or FOLFIRI) works better for advanced small bowel adenocarcinoma that has already been treated with certain prior medicines. It may help shrink tumors or slow cancer growth in people whose cancer has progressed.
Anchorage, AlaskaAges 18 years+ - NCT06026943Recruiting
Alpha radiation therapy for locally advanced pancreatic cancer
This trial tests a new treatment that uses tiny alpha radiation sources placed directly into the tumor to destroy cancer cells. It is for people with pancreatic cancer that has not spread but cannot be removed surgically, and who have already tried at least one type of chemotherapy or cannot take more chemo.
VeronaAges 18–120 - NCT07817147Recruiting
Microwave ablation treatment for advanced cancer
This study tests a procedure called microwave ablation (using heat to destroy cancer cells) for tumors that are hard to remove with surgery. It aims to see if the procedure is safe and effective when done through a scope in the stomach.
Gilbert, ArizonaAges 18 years+ - NCT05254171RecruitingPhase 2/Phase 3
Trial adds SBP-101 to standard chemo for pancreatic cancer
This trial studies whether adding SBP-101 to standard chemotherapy (gemcitabine plus nab-paclitaxel) can improve outcomes in people with metastatic pancreatic cancer. You may be eligible if you have not yet started treatment for metastatic disease and meet other health and test requirements.
Hot Springs, ArkansasAges 18 years+ - NCT06532799RecruitingPhase 1/Phase 2
TIL therapy with pembrolizumab for advanced stomach and esophageal cancer
This trial tests a combination of immune cells from your tumor (TILs) and an immunotherapy drug (pembrolizumab) for stomach or esophageal cancer that has spread or returned after other treatments. It may help if standard options have failed.
Beijing, Beijing MunicipalityAges 16–90 - NCT07595237RecruitingEarly Phase 1
Radioactive treatment for advanced solid tumors with Claudin18.2
This early-stage trial tests a new radioactive drug (177Lu-DOTA-SNA040) designed to target a protein called Claudin18.2 found on certain cancer cells. The drug delivers radiation directly to tumors in patients with advanced gastric, pancreatic, or bile duct cancers that have stopped responding to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06387342RecruitingPhase 2
Namodenoson for advanced pancreatic cancer
This trial tests an oral drug called Namodenoson for people with advanced pancreatic cancer that has not responded to previous treatments. The goal is to see if the drug can help slow the cancer's growth or improve symptoms.
Petah TikvaAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Goodyear, ArizonaAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Denver, ColoradoAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,823 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.